ID

34401

Descrição

Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib; ODM derived from: https://clinicaltrials.gov/show/NCT01514448

Link

https://clinicaltrials.gov/show/NCT01514448

Palavras-chave

  1. 17/01/2019 17/01/2019 -
Titular dos direitos

see on clinicaltrials.gov

Transferido a

17 de janeiro de 2019

DOI

Para um pedido faça login.

Licença

Creative Commons BY 4.0

Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Metastatic Renal Cell Carcinoma (mRCC) NCT01514448

Eligibility Metastatic Renal Cell Carcinoma (mRCC) NCT01514448

Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients with advanced renal cell carcinoma of a histological or cytological confirmation of clear cell renal carcinoma.
Descrição

ID.1

Tipo de dados

boolean

progression during or after a treatment with sunitinib or pazopanib given in a 1st line treatment situation for mrcc.
Descrição

ID.2

Tipo de dados

boolean

patients scheduled for treatment with everolimus.
Descrição

ID.3

Tipo de dados

boolean

patients with at least one measurable lesion at baseline.
Descrição

ID.4

Tipo de dados

boolean

Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients who have received >1 prior systemic treatment for their metastatic rcc. prior systemic treatment in an adjuvant setting is allowed.
Descrição

ID.5

Tipo de dados

boolean

patients who have previously received systemic mtor inhibitors (e.g. sirolimus, temsirolimus, everolimus).
Descrição

ID.6

Tipo de dados

boolean

patients who are using other investigational agents or who had received investigational drugs ≤ 2 weeks prior to study treatment start.
Descrição

ID.7

Tipo de dados

boolean

patients unwilling or unable to comply with the protocol.
Descrição

ID.8

Tipo de dados

boolean

other protocol-defined inclusion/exclusion criteria may apply.
Descrição

ID.9

Tipo de dados

boolean

Similar models

Eligibility Metastatic Renal Cell Carcinoma (mRCC) NCT01514448

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
patients with advanced renal cell carcinoma of a histological or cytological confirmation of clear cell renal carcinoma.
boolean
ID.2
Item
progression during or after a treatment with sunitinib or pazopanib given in a 1st line treatment situation for mrcc.
boolean
ID.3
Item
patients scheduled for treatment with everolimus.
boolean
ID.4
Item
patients with at least one measurable lesion at baseline.
boolean
Item Group
C0680251 (UMLS CUI)
ID.5
Item
patients who have received >1 prior systemic treatment for their metastatic rcc. prior systemic treatment in an adjuvant setting is allowed.
boolean
ID.6
Item
patients who have previously received systemic mtor inhibitors (e.g. sirolimus, temsirolimus, everolimus).
boolean
ID.7
Item
patients who are using other investigational agents or who had received investigational drugs ≤ 2 weeks prior to study treatment start.
boolean
ID.8
Item
patients unwilling or unable to comply with the protocol.
boolean
ID.9
Item
other protocol-defined inclusion/exclusion criteria may apply.
boolean

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial